Blocking a specific protein to prevent lung scarring
Official title: Inhibition of Fgr Prevents Pulmonary Fibrosis
Funded at University of Pittsburgh at Pittsburgh · NIH-10901018 · Data updated 2026-11-12
This study is looking at how a new drug that targets a protein called Fgr might help prevent lung scarring in people with pulmonary fibrosis, aiming to protect healthy cells while reducing damage.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $325,950 |
| NIH project number | 1R56AG083346-01 |
| Project ID | NIH-10901018 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with pulmonary fibrosis, particularly those with idiopathic pulmonary fibrosis or fibrosis resulting from COVID-19.
✕Less likely to help
Patients with other forms of lung disease unrelated to fibrosis may not benefit from this research.
What this research studies
This research investigates how targeting a specific protein called Fgr can help prevent pulmonary fibrosis, a condition that causes scarring in the lungs. The approach involves using a drug that inhibits Fgr, which has been shown to play a role in the development of fibrosis in senescent cells. By focusing on this specific target, the research aims to reduce harmful effects while preserving beneficial cells. The study will utilize advanced techniques like RNA sequencing to understand the mechanisms involved in fibrosis better.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively prevent or reduce lung scarring in patients.
How similar studies have gone: Previous research has shown promise in targeting specific proteins to mitigate fibrosis, suggesting that this approach could be effective.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Mukherjee, Amitava — University of Pittsburgh at Pittsburgh
- Study coordinator: Mukherjee, Amitava
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.